Authors
Carlo Piccinni, Letizia Dondi, Nicola Ambrosio, Leonardo Dondi, Giulia Ronconi, Irene Dell'Anno, Alice Addesi, Immacolata Esposito, Nello Martini, Aldo Pietro Maggioni
Published in
Recenti progressi in medicina. Volume 117. Issue 7-8. Pages 350-357.
Abstract
This study analyses, within Italian clinical practice, the epidemiology, healthcare resource utilization, and direct costs for the National Health Service (NHS) of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
From the ReS healthcare administrative database (4.6 million beneficiaries in 2022), patients with ATTR-CM were identified (2014-2022) through dispensation of tafamidis 61 mg or diagnosis of heart failure/arrhythmic cardiomyopathy with a compatible diagnostic work-up. Prevalence, clinical characteristics, mortality, treatments, healthcare resource utilization, and costs were estimated during the 1-year follow-up.
867 patients with ATTR-CM were identified in 2022 (male: 63%; mean age: 73 years; ≥3 comorbidities: 88.6%). During follow-up, 13% of patients died; 46% were hospitalized under ordinary care; 46.8% visited the emergency department; 96.5% received outpatient specialist care. Tafamidis 61 mg was dispensed to 49 patients (5.7%). The average annual cost per patient, borne by the NHS, was €17,284 (59.7% attributable to pharmaceuticals).
The impact of ATTR-CM on the NHS is considerable, due to advanced patient age, multimorbidity, polypharmacy, and frequent hospitalizations, both related and unrelated to ATTR-CM.
PMID:
42459101
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0